Drug Trial Radar · NCT02656329
International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device
Last checked: Nov 19, 2026Latest source record: May 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
395
Actual
Start
Dec 30, 2015
Primary completion
May 4, 2018
Study completion May 4, 2018
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- Advanced Clinical, LLC; TFS; H2O Clinical LLC; AG Mednet; ICON plc; ABX CRO; TransPerfect
- First posted
- Jan 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an event-driven Phase IIIb, multicentre, randomised, clinical study to demonstrate the efficacy of AdreView™ imaging for appropriately guiding the decision of implantable cardioverter defibrillator (ICD) implantation, in New York Health Association (NYHA) class II and III heart failure participants with 25%\<=left ventricular ejection fraction (LVEF)\<=35%, and in particular, for identifying participants who are at low risk for sudden cardiac death and who would not benefit, or may suffer harm, from implantation of an ICD device.
Conditions
- Heart Failure
Interventions
Iobenguane I -123 InjectionDrug
Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
Implantable Cardioverter DefibrillatorDevice
In the Iobenguane I-123 Injection group, participants with H/M ratio less or equal to 1.6 underwent ICD device implantation, while those with H/M ratio greater than or equal to 1.6 did not undergo ICD implantation.
Thyroid blockingDrug
Participants received a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
Iobenguane I -123 InjectionDrug
Iobenguane I-123 Injection, AdreView. All participants scheduled for an Iobenguane I-123 Injection, AdreView scan.
Implantable Cardioverter DefibrillatorDevice
All participants allocated to the SoC (control) group underwent ICD implantation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All-cause MortalityTime frame: From randomization until the end of the follow-up period (median 304 days)
Locations
94 sites in 10 countries. Site status is shown where the registry gives one.
Vascular Biology and Hypertension Program, University of Alabama at Birmingham
Birmingham, Alabama
Comprehensive Cardiovascular Medical Group
Bakersfield, California
Sharp Grossmont Hospital
La Mesa, California
Yale New Haven Hospital
New Haven, Connecticut
VA Connecticut Healthcare System (VACHS)
West Haven, Connecticut
Cardiology Physicians PA/Red Clay Research, LLC
Newark, Delaware
Bethesda Health
Boynton Beach, Florida
University of Florida Health Jacksonville
Jacksonville, Florida
University of Miami Hospital
Miami, Florida
Cardiology Consultants
Pensacola, Florida
South Miami Heart Specialists
South Miami, Florida
Tampa General Hospital
Tampa, Florida
University of South Florida
Tampa, Florida
Augusta University
Augusta, Georgia
Rush University Medical Center
Chicago, Illinois
Northwestern University
Evanston, Illinois
MMP ME Health Cardiology
Scarborough, Maine
MedStar Shah Medical Group
Charlotte Hall, Maryland
Boston Medical Center
Boston, Massachusetts
Department of Cardiology, K-14 (Henry Ford Health System)
Detroit, Michigan
Regions Hospital and Regions Heart Center Clinic
Saint Paul, Minnesota
University at Buffalo
Buffalo, New York
Advanced Cardiology Group
Buffalo, New York
Montefiore Medical Center
The Bronx, New York
WakeMed
Raleigh, North Carolina
Veterans Affairs North Texas Healthcare System
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
Texas Institute of Cardiology, PA
McKinney, Texas
Victoria Heart and Vascular Center
Victoria, Texas
Institut Universitaire De Cardiologie Et De Pneumologie De Quebec
Québec, Canada
University of Calgary
Calgary, Alberta, Canada
Royal Alexandra Hospital
Edmonton, Alberta, Canada
London Health Sciences Centre
London, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
CIUSSS de L'Estrie - CHUS Hopital Fleurimont
Sherbrooke, Quebec, Canada
Fakultni nemocnice Brno Bohunice
Brno, Czechia
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
FN Hradec Kralove
Hradec Králové, Czechia
Krajska nemocnice Liberec
Liberec, Czechia
Showing 40 of 94 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.